Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Imatinib/Rapamycin Gradient Encoding, mRNA abundance

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE35051 | GEO | 2013/01/10

SECONDARY ACCESSION(S): PRJNA150841

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Imatinib/Rapamycin Gradient Encoding, mRNA abundance

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-01-10 | E-GEOD-35051 | biostudies-arrayexpress

Imatinib/Rapamycin Gradient Encoding

Project description:The purpose of this study was to compare changes in translation (using Gradient Encoding, described below) to changes in mRNA abundance. Lysates of wildtype v-Abl transformed pre-B cells harvested before and after 12 hours of treatment either with 2.5 uM imatinib, a v-Abl kinase inhibitor, or 10ng/mL (10.9 nM) rapamycin, an mTOR inhibitor, were fractionated by sedimentation through linear sucrose gradients. Gradient fractions were encoded such that the mRNA from successive fractions was labeled with increasing ratios of Cy5 to Cy3. mRNAs derived from fractions in the lighter portion of the gradient therefore have a lower Cy5 to Cy3 ratio, whereas those deeper in the gradient have a higher Cy5 to Cy3 ratio. The ratio of Cy5 to Cy3 for each mRNA therefore reflects its average position within the gradient. We thus encoded the sedimentation rate of each mRNA across the entire gradient. The resulting ratios were quantitatively measured for each mRNA species by hybridization to DNA microarrays, and related to the 260 nm absorbance peaks representing different numbers of ribosomes bound per mRNA Compound Based Treatment: wildtype v-Abl transformed pre-B cells were treated with imatinib mesylate (IMA), rapamycin (RAP) or nothing (NONE)

2013-01-10 | GSE35039 | GEO

Imatinib/Rapamycin Gradient Encoding

2013-01-10 | E-GEOD-35039 | biostudies-arrayexpress

Imatinib/Rapamycin mRNA abundance

Project description:Measurement of mRNA abundance from the following cells lines (red) versus universal mouse reference RNA (green). Wildtype v-Abl transformed pre-B cells were treated for 12 hours with 2.5 uM imatinib mesylate, 10ng/mL rapamycin or nothing. Compound Based Treatment: wildtype v-Abl transformed pre-B cells were treated with imatinib mesylate (IMA), rapamycin (RAP) or nothing (NONE)

2013-01-10 | GSE35040 | GEO

Imatinib/Rapamycin mRNA abundance

2013-01-10 | E-GEOD-35040 | biostudies-arrayexpress

The effect of Rapamycin on the transcriptome of old mouse liver

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-02-07 | E-GEOD-48334 | biostudies-arrayexpress

A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-11-25 | E-GEOD-75358 | biostudies-arrayexpress

Expression profiling in extracellular miRNAs of CML patients after imatinib discontinuation (STOP-IM)

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-03-31 | E-GEOD-75392 | biostudies-arrayexpress